Caribou Inks Drug Target Research, Investment Agreements with Novartis

Jan 07, 2015 | a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – Caribou Biosciences announced today that it has signed a deal under which it will use its CRISPR/Cas 9 gene-editing technology for the discovery and validation of new drug targets for Novartis.

Concurrent with the agreement, Novartis has also taken an undisclosed equity stake in Caribou through a Series A investment round.

Caribou will receive research funding from Novartis under the one-year term of the agreement, and it has also provided Novartis with an option to non-exclusively license its CRISPR/Cas 9 platform for research applications.

Additional terms were not disclosed.

Filed Under Gene Expression Research | Drug Discovery & Development | Business News | equity investment | collaboration | Novartis

Related Articles

Sep 06, 2016
Horizon Discovery, Fulcrum Therapeutics Collaborate on Target Discovery Using CRISPR Screens

Apr 12, 2016
Intellia Files for $120M IPO, Inks Lucrative Collaboration With Regeneron

May 16, 2016
Caribou Biosciences Raises $30M in Series B Funding

Sep 21, 2016

Companies Collaborate on CRISPR Guide RNA Libraries With Lentiviral Vector Delivery

Oct 26, 2015

CRISPR Therapeutics, Vertex Pharmaceuticals Ink $105M Collaboration Deal

Jan 29, 2016

AstraZeneca Shows Off Quick Uptake of CRISPR Tech in Drug Discovery Process

We recommend

Caribou Biosciences Raises $11M in Series A Funding
GenomeWeb, 2015

DuPont, Caribou Biosciences Ink Strategic Alliance on CRISPR, Cross-License IP
GenomeWeb, 2015

Intellia Files for $120M IPO, Inks Lucrative Collaboration With Regeneron
GenomeWeb, 2016

Caribou Biosciences Raises $30M in Series B Funding
GenomeWeb, 2016

Caribou Biosciences, Genus Ink CRISPR Deal to Develop New Traits in Livestock
GenomeWeb, 2016

Caribou Bio Grants IDT Non-Exclusive Rights to Commercialize RUO CRISPR/Cas9 Reagents
GenomeWeb, 2016

Powered by TrendMD

Privacy Policy. Copyright © 2016 Genomeweb LLC. All Rights Reserved.